Title of article
Circulating tumor DNA applications in treatment monitoring of metastatic colorectal cancer patients
Author/Authors
Kazemifard, Nesa Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Sadeghi, Amir Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Varaminian, Behnaz Department of Hematology and Medical Oncology - Shahid Beheshti University of Medical Sciences , Rezvani, Hamid Department of Hematology and Medical Oncology - Shahid Beheshti University of Medical Sciences , Ayadi, Ahmad Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Talaie, Ramin Laboratory of Experimental Therapies in Oncolog - IRCCS Istituto Giannina Gaslini - Italy , Moshiri, Arfa Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences
Pages
8
From page
14
To page
21
Abstract
Colorectal cancer is the third most common cancer worldwide. New cancer treatment strategies such as monoclonal antibodies against growth factor and angiogenesis receptors have improved the overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC) patients. However, acquired resistance could happen after these therapies. Circulating tumor DNA (ctDNA) is the DNA fraction derived from tumor cells which could be applied as a non-invasive method for detecting tumor mutations before, during, and after therapies. Here, we reviewed most of the studies examining ctDNA as treatment monitoring in mCRC patients who receive different target therapies. Also, we compared ctDNA with other existing cancer-treatment monitoring methods.
Keywords
Circulating tumor DNA , Colorectal cancer , Treatment monitoring
Journal title
Gastroenterology and Hepatology From Bed to Bench
Serial Year
2019
Record number
2500747
Link To Document